Focusing on the "she economy", domestic and foreign pharmaceutical companies are pouring into the field of women's health

Recently, Maven Clinic, a virtual clinic for women and family health, announced the completion of $90 million Series E financing
.
It is understood that Maven plans to use the new round of financing to advance the end-to-end home care platform to achieve a deeper level of personalization to meet the diverse needs
of women and families everywhere.
For Maven Clinic's financing, the industry believes that it is a manifestation
of the rise of the "she economy".
In recent years, with the rise of the female population, the increase of work and life pressure, the improvement of living standards and health awareness, etc.
, gynecological diseases have received more and more attention, thereby catalyzing the rapid expansion of the gynecological health consumer goods market, in order to meet the growing market demand, many pharmaceutical companies have poured into the field of women's health and are accelerating the layout
.
At present, multinational pharmaceutical companies are more active in the field of women's health, and many results
have emerged.
It is understood that at the fifth China International Import Expo, a large number of multinational pharmaceutical companies focused on women's health topics and exhibited a series of products
focusing on women's health and medical beauty.
For example, on November 6, Abbott released the OTC combination oral short-acting contraceptive Youwele ®
.
It is understood that the "first in China" combination oral short-acting contraceptive pill has safe and reliable ingredients, can achieve efficient and safe contraceptive effect, and at the same time effectively regularize the menstrual cycle and improve premenstrual syndrome
.
AstraZeneca brings a new product in the field of women's oncology - Enhertu*
.
It is understood that the drug is an antibody conjugate drug jointly developed by AstraZeneca and Daiichi Sankyo targeting human epidermal growth receptor 2 (HER2), which has not yet been approved
in China.
In addition to unveiling the nine-valent human papillomavirus vaccine (HPV vaccine) at this Expo, Merck also presented ten years of support for promoting the cervical health of
Chinese women.
It is reported that in 2013, Merck and the China Women's Development Foundation launched the "China Women's Cervical Health Promotion Program", and as of 2021, the "China Women's Cervical Health Promotion Program" has covered more than 80 cities across the country, benefiting 90 million Chinese women and their families
。 In addition, Allergan Aesthetics launched the upgraded CoolPlastic ® Cryoli Reduction Device and the new generation of CoolAdvantage™ series applicators, Organon exhibited and demonstrated the concept of "Fertility-friendly Future Community", and Celifu launched the world's first health product focusing on women's ovarian health.
.
.
It is clear from the above that the "she economy" has gradually become the focus
of attention of multinational pharmaceutical companies.
In fact, women's health issues have always been a global problem, and in recent years, China has also increased its attention to the women's health industry, such as China's "14th Five-Year Plan", which regards women's health services as an important part of promoting the level of
medical sharing and improving people's livelihood.
The Outline for the Development of Chinese Women (2021-2030) issued by the state in September 2021 also listed "women and health" as the first
priority development area.
Affected by this, domestic pharmaceutical companies have already begun to increase the layout of the women's health market
.
For example, on December 11, 2020, Kinsey Pharmaceutical signed a cooperation agreement with Salubris to transfer all technical ownership and intellectual property rights of the investigational variety "recombinant human follicle-stimulating hormone-CTP fusion protein injection" developed by Chengdu Salubris in the phase I clinical trial stage to Chinese mainland Kinsey Pharmaceutical
.
Industry analysts believe that with the rise of China's female population, the increase of work and life pressure, the improvement of living standards and health awareness, etc.
, the women's health market will attract more and more domestic and foreign pharmaceutical companies, which will also promote the further development of
China's women's health service industry.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.